latozinemab

Monoclonal antibody

DiscontinuedSortilin
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2025-10), after a negative readout

INFRONT-3 missed its clinical co-primary endpoint (October 2025); Alector abandoned latozinemab in FTD-GRN and GSK ended the alliance. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Featured evidence outside this drug's tracked markets:NCT06111014 · Neurodegenerative Diseases · Phase 3 · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT06111014 · Alector Inc.
2023-12-08 – 2026-01-07 · Neurodegenerative Diseases
What this study did
Phase 2 (1)
Other / comorbidity
NCT03987295 · Alector Inc.
2019-09-27 – 2024-06-05 · Frontotemporal Dementia
What this study did
Phase 1 (1)
Other / comorbidity
NCT03636204 · Alector Inc.
2018-09-14 – 2019-12-31 · Healthy, Frontotemporal Dementia
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Latozinemab: this drugDiscontinuedMonoclonal antibodySortilinnot yet gradedNo reviewed efficacy summary
Nivisnebart
Discontinued
Monoclonal antibodySortilinnot yet gradedNo reviewed efficacy summary

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 October 2025Topline resultPhase 3 INFRONT-3 topline
Alector · Source ↗